Abbott Laboratories (ABT)vsEdwards Lifesciences Corp (EW)
ABT
Abbott Laboratories
$89.46
-2.15%
HEALTHCARE · Cap: $155.82B
EW
Edwards Lifesciences Corp
$83.98
+0.57%
HEALTHCARE · Cap: $48.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 616% more annual revenue ($45.13B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 13.9%. ABT appears more attractively valued with a PEG of 1.33. EW earns a higher WallStSmart Score of 61/100 (C+).
ABT
Buy56
out of 100
Grade: C
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-0.1%
Fair Value
$87.50
Current Price
$89.46
$1.96 premium
Margin of Safety
+69.9%
Fair Value
$263.84
Current Price
$83.98
$179.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 31.2%
16.7% revenue growth
Areas to Watch
Moderate valuation
Weak financial health signals
Earnings declined 19.7%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.4x leaves little room for execution misses.
Key Dynamics to Monitor
ABT profiles as a value stock while EW is a growth play — different risk/reward profiles.
EW carries more volatility with a beta of 0.94 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 56/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?